Sahil Khanna1, Emmanuel Montassier2,3, Bradley Schmidt1, Robin Patel4,5, Daniel Knights3, Darrell S Pardi1, Purna Kashyap1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. 2. EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, Faculté de Médecine, Université de Nantes, Nantes, France. 3. Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN. 4. Division of Infectious Diseases, Mayo Clinic, Rochester, MN. 5. Division of Clinical Microbiology, Department of Medicine, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) may not respond to initial therapy and frequently recurs, but predictors of response and recurrence are inconsistent. The impact of specific alterations in the gut microbiota determining treatment response and recurrence in patients with CDI is unknown. AIM: To assess microbial signatures as predictors of treatment response and recurrence in CDI. METHODS: Pre-treatment stool samples and clinical metadata including outcomes were collected prospectively from patients with their first CDI episode. Next generation 16s rRNA sequencing using MiSeq Illumina platform was performed and changes in microbial community structure were correlated with CDI outcomes. RESULTS: Eighty-eight patients (median age 52.7 years, 60.2% female) were included. Treatment failure occurred in 12.5% and recurrence after response in 28.5%. Patients who responded to treatment had an increase in Ruminococcaceae, Rikenellaceae, Clostridiaceae, Bacteroides, Faecalibacterium and Rothia compared to nonresponders. A risk-index built from this panel of microbes differentiated responders (mean 0.07 ± 0.24) from nonresponders (0.52 ± 0.42; P = 0.0002). Receiver operating characteristic (ROC) curve demonstrated that risk-index was a strong predictor of treatment response with an area under the curve (AUC) of 0.85. Among clinical parameters tested, only proton pump inhibitor use predicted recurrent CDI (OR 3.75, 95% CI 1.27-11.1, P = 0.01). Patients with recurrent CDI had statistically significant increases in Veillonella, Enterobacteriaceae, Streptococci, Parabacteroides and Lachnospiraceae compared to patients without recurrence and a risk index was able to predict recurrence (AUC = 0.78). CONCLUSION: Gut microbiota signatures predict treatment response and recurrence potentially, allowing identification of patients with Clostridium difficile infection that may benefit from early institution of alternate therapies.
BACKGROUND:Clostridium difficileinfection (CDI) may not respond to initial therapy and frequently recurs, but predictors of response and recurrence are inconsistent. The impact of specific alterations in the gut microbiota determining treatment response and recurrence in patients with CDI is unknown. AIM: To assess microbial signatures as predictors of treatment response and recurrence in CDI. METHODS: Pre-treatment stool samples and clinical metadata including outcomes were collected prospectively from patients with their first CDI episode. Next generation 16s rRNA sequencing using MiSeq Illumina platform was performed and changes in microbial community structure were correlated with CDI outcomes. RESULTS: Eighty-eight patients (median age 52.7 years, 60.2% female) were included. Treatment failure occurred in 12.5% and recurrence after response in 28.5%. Patients who responded to treatment had an increase in Ruminococcaceae, Rikenellaceae, Clostridiaceae, Bacteroides, Faecalibacterium and Rothia compared to nonresponders. A risk-index built from this panel of microbes differentiated responders (mean 0.07 ± 0.24) from nonresponders (0.52 ± 0.42; P = 0.0002). Receiver operating characteristic (ROC) curve demonstrated that risk-index was a strong predictor of treatment response with an area under the curve (AUC) of 0.85. Among clinical parameters tested, only proton pump inhibitor use predicted recurrent CDI (OR 3.75, 95% CI 1.27-11.1, P = 0.01). Patients with recurrent CDI had statistically significant increases in Veillonella, Enterobacteriaceae, Streptococci, Parabacteroides and Lachnospiraceae compared to patients without recurrence and a risk index was able to predict recurrence (AUC = 0.78). CONCLUSION: Gut microbiota signatures predict treatment response and recurrence potentially, allowing identification of patients with Clostridium difficileinfection that may benefit from early institution of alternate therapies.
Authors: Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly Journal: Gastroenterology Date: 2008-12-13 Impact factor: 22.682
Authors: Susan E Pryde; Sylvia H Duncan; Georgina L Hold; Colin S Stewart; Harry J Flint Journal: FEMS Microbiol Lett Date: 2002-12-17 Impact factor: 2.742
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower Journal: Genome Biol Date: 2012-04-16 Impact factor: 13.583
Authors: David W Eyre; A Sarah Walker; David Wyllie; Kate E Dingle; David Griffiths; John Finney; Lily O'Connor; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Timothy E A Peto Journal: Clin Infect Dis Date: 2012-08 Impact factor: 9.079
Authors: Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer Journal: Nature Date: 2014-10-22 Impact factor: 49.962
Authors: Maribeth R Nicholson; Paul D Mitchell; Erin Alexander; Sonia Ballal; Mark Bartlett; Penny Becker; Zev Davidovics; Michael Docktor; Michael Dole; Grace Felix; Jonathan Gisser; Suchitra K Hourigan; M Kyle Jensen; Jess L Kaplan; Judith Kelsen; Melissa Kennedy; Sahil Khanna; Elizabeth Knackstedt; McKenzie Leier; Jeffery Lewis; Ashley Lodarek; Sonia Michail; Maria Oliva-Hemker; Tiffany Patton; Karen Queliza; George H Russell; Namita Singh; Aliza Solomon; David L Suskind; Steven Werlin; Richard Kellermayer; Stacy A Kahn Journal: Clin Gastroenterol Hepatol Date: 2019-04-19 Impact factor: 11.382
Authors: Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Allen A Lee; Krishna Rao; Julajak Limsrivilai; Merritt Gillilland; Benjamin Malamet; Emily Briggs; Vincent B Young; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2020-10-23 Impact factor: 5.325
Authors: Melinda A Engevik; Heather A Danhof; Jennifer Auchtung; Bradley T Endres; Wenly Ruan; Eugénie Bassères; Amy C Engevik; Qinglong Wu; Maribeth Nicholson; Ruth Ann Luna; Kevin W Garey; Sue E Crawford; Mary K Estes; Renate Lux; Mary Beth Yacyshyn; Bruce Yacyshyn; Tor Savidge; Robert A Britton; James Versalovic Journal: Gastroenterology Date: 2020-11-21 Impact factor: 22.682